Drug Profile


Latest Information Update: 09 Aug 2002

Price : $50

At a glance

  • Originator Laboratoire M. Richard
  • Class Indoleacetic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 22 Apr 1997 Three studies in patients with rheumatic disorders have been added to the therapeutic trials and adverse effects sections ,,
  • 22 Apr 1997 Investigation in Ankylosing spondylitis in France (PO)
  • 22 Apr 1997 Investigation in Osteoarthritis in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top